Do peptides help with fat loss and body composition?
8 peptides are graded for fat loss and body composition on this page. The strongest grade is human RCT evidence, for semaglutide, tirzepatide, tesamorelin, tesofensine, and HCG (human chorionic gonadotropin). Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.
What is the standard of care for fat loss and body composition?
A sustained calorie deficit with adequate protein, resistance training to preserve lean mass, and adequate sleep; FDA approved anti-obesity medication when BMI criteria are met (30 or higher, or 27 or higher with a weight related condition). Fat loss for appearance alone is not an approved drug indication.
Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.
Which peptides have been studied for fat loss and body composition?
Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.
| Peptide | Evidence for this use | Note |
|---|---|---|
| Semaglutide | Evidence: Human RCT evidence | STEP 1: 14.9% mean weight loss with 2.4 mg over 68 weeks versus 2.4% on placebo; FDA approved as Wegovy for chronic weight management. [1] [7] |
| Tirzepatide | Evidence: Human RCT evidence | SURMOUNT-1: 20.9% mean weight loss at 15 mg over 72 weeks; FDA approved as Zepbound. [2] [8] |
| Tesamorelin | Evidence: Human RCT evidence | Visceral fat fell about 15% versus placebo over 26 weeks in adults with HIV associated abdominal fat excess, the only population it is approved for. [3] [9] |
| Tesofensine | Evidence: Human RCT evidence | Phase 2 weight loss of 6.7 to 12.8 kg versus 2.2 kg on placebo over 24 weeks, with dose related heart rate and blood pressure increases; a small molecule, not approved. [4] |
| HCG (human chorionic gonadotropin) | Evidence: Human RCT evidence | Controlled trials of the hCG diet found no added weight loss, fat redistribution, or hunger reduction beyond the very low calorie diet; FDA says hCG is not approved for weight loss. [5] [6] [10] |
| AOD-9604 | Evidence: Animal-only evidence | Increased fat oxidation in obese mice; small human studies reported no meaningful fat loss and do not raise the grade. [11] |
| 5-Amino-1MQ | Evidence: Animal-only evidence | Small molecule NNMT inhibitor that reduced fat mass in diet induced obese mice; no human studies. [12] |
| Adipotide | Evidence: Animal-only evidence | Produced about 11% weight loss in obese monkeys with reversible kidney toxicity; no human efficacy data. [13] |
Head-to-head comparisons
Cost and access
Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.
Frequently asked questions
What are the best peptides for fat loss?
The peptides with proven fat loss are FDA approved prescription drugs. Tirzepatide (Zepbound) produced 20.9% mean weight loss at its highest dose in SURMOUNT-1 and semaglutide (Wegovy) 14.9% in STEP 1, and tesamorelin (Egrifta) cut visceral fat by about 15% versus placebo, but only in adults with HIV associated abdominal fat excess. AOD-9604, 5-amino-1MQ, and adipotide have animal data only, and hCG diets add nothing beyond the calorie restriction. [1] [2] [3] [5] [11] [12] [13]
Is any peptide FDA approved for fat loss and body composition?
Semaglutide, tirzepatide, tesamorelin, and HCG (human chorionic gonadotropin) are FDA approved drugs, but an approval covers only the indications on that label, so check the label before assuming it applies to fat loss and body composition. The other peptides graded here are not FDA approved. [1] [2] [7] [8] [14]
Has any peptide been tested in a randomized trial for fat loss and body composition?
Yes, for semaglutide, tirzepatide, tesamorelin, tesofensine, and HCG (human chorionic gonadotropin). Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [1] [2] [7] [8]
From the blog
- 5-amino-1MQ for fat loss: mouse data, no human trials
5-amino-1MQ reduced fat mass in obese mice, but no human study of any kind has been published. What the mouse studies found, capsules vs injection, side effects, and legal status.
- Does tesamorelin build muscle? What the trials show
Tesamorelin raised lean body mass about 1.2 kg in HIV trials and slightly increased trunk muscle area, but no trial tested strength or muscle growth, and it is prohibited in sport.
- Peptide stacks: what each common component has shown alone
No trial has tested a multi-peptide stack for muscle growth or fat loss. Nine common stack components ranked by their own human evidence, legal status, and WADA status. No protocols.
- Peptides for weight loss, ranked by human evidence
Tirzepatide, semaglutide, and liraglutide lead on human trials. Retatrutide is trial-only, and AOD-9604 and 5-amino-1MQ are animal-only. Ranking, legal status, and dated prices.
- Tesamorelin before and after: what the trials measured
Tesamorelin results from the 26 and 52 week trials: about 15 to 18% less visceral fat, little change in weight, and fat that came back after stopping. Why photos are not trial data.
- Tesamorelin prescription: who qualifies and how to get one
How to get tesamorelin legally: who qualifies for Egrifta WR on label, how off-label prescribing works, why compounded tesamorelin is not lawful, what a visit should check, and cost.
Sources
- [1]Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021 (STEP 1)PubMed 33567185, 2021
- [2]Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022 (SURMOUNT-1)PubMed 35658024, 2022
- [3]Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension dataPubMed 20554713, 2010
- [4]Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trialPubMed 18950853, 2008
- [5]The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysisPubMed 8527285, 1995
- [6]FDA consumer update: Avoid dangerous HCG diet products (hCG is not approved for weight loss; over the counter hCG products are illegal)FDA, 2025
- [7]FDA prescribing information for Wegovy (semaglutide) injection, via DailyMedFDA, 2025
- [8]FDA prescribing information for Zepbound (tirzepatide) injection, via DailyMedFDA, 2025
- [9]FDA prescribing information for Egrifta SV (tesamorelin for injection), via DailyMedFDA, 2025
- [10]FDA prescribing information for Pregnyl (chorionic gonadotropin for injection), via DailyMedFDA, 2025